Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

ThatNurseDude Dec. 24 at 3:29 PM

$PDSB think I found the ad https://ispot.tv/a/B9OW looks like they used ai to make it.

2 · Reply

Mr_Charlie Dec. 24 at 2:26 PM

$PDSB still another week left to buy at a very discounted price. From 5 Jan I think this will start to move up.

0 · Reply

jeffs10 Dec. 24 at 1:31 PM

$PDSB What is everyone's thoughts on the current commercial that's been airing on CNBC? Yesterday between 11A and 3P I saw the commercial three times. Since I've owned the stock, I've never seen any advertising let alone frequent airing on CNBC.

6 · Reply

Ontherag Dec. 23 at 1:51 AM

$PDSB I’m assuming the trial will resume right after meeting with FDA? It would make no sense to wait for FDA minutes…

1 · Reply

Ontherag Dec. 22 at 6:29 PM

$PDSB We should have immediate approval for CPS > 20. Very sad for these patients. I know Frank had made mistakes but between the FDA and this market, it’s tough to swallow. Betting on binary decisions is never a good idea and here we are. GL.

1 · Reply

ThatNurseDude Dec. 22 at 6:18 PM

$PDSB If FDA doesn’t give us good news in January, this’ll be such a huge blunder for all- especially for patients with no other options. PDS has so many potential applications. We need validation!

1 · Reply

Eddie5150 Dec. 22 at 6:12 PM

$PDSB $XBI ⬆️ this 💩 ⬇️ as usual.

0 · Reply

EddieH2020 Dec. 22 at 4:27 PM

Since I last sold the turd $PDSB - it is only up 6% while SLS is up over 70% in the same time period, pending Phase 3 trial results any day now. This is why it’s important to cut turds fast and buy the best stocks. Just some of my position below. You can’t say I didn’t give you all the heads up ahead of time 👍

1 · Reply

Mr_Charlie Dec. 22 at 4:23 PM

$PDSB most companies green today but we have to be red. No faith in our company what-so-ever. I hope all of them get it wrong and this will cause a big noise in January.

0 · Reply

JohntyCT Dec. 22 at 3:03 PM

$PDSB we have some volume today… 🫣 … 200k traded by 10 am….

1 · Reply

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 23 days ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 10:11 AM EST - 6 weeks ago

PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:30 AM EST - 6 weeks ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 6 weeks ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 6 weeks ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 7 weeks ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 2 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 2 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 3 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 4 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 10:08 AM EDT - 4 months ago

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 4 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 7 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 12:57 PM EDT - 8 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 8 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 8 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 8 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 10:35 AM EDT - 9 months ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 9 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 10 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 11 months ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 11:18 AM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 23, 2024, 10:39 AM EDT - 1 year ago

PDS Biotechnology: Continuing The Holding Pattern

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 2, 2024, 9:12 AM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

ThatNurseDude Dec. 24 at 3:29 PM

$PDSB think I found the ad https://ispot.tv/a/B9OW looks like they used ai to make it.

2 · Reply

Mr_Charlie Dec. 24 at 2:26 PM

$PDSB still another week left to buy at a very discounted price. From 5 Jan I think this will start to move up.

0 · Reply

jeffs10 Dec. 24 at 1:31 PM

6 · Reply

Ontherag Dec. 23 at 1:51 AM

$PDSB I’m assuming the trial will resume right after meeting with FDA? It would make no sense to wait for FDA minutes…

1 · Reply

Ontherag Dec. 22 at 6:29 PM

1 · Reply

ThatNurseDude Dec. 22 at 6:18 PM

1 · Reply

Eddie5150 Dec. 22 at 6:12 PM

$PDSB $XBI ⬆️ this 💩 ⬇️ as usual.

0 · Reply

EddieH2020 Dec. 22 at 4:27 PM

1 · Reply

Mr_Charlie Dec. 22 at 4:23 PM

$PDSB most companies green today but we have to be red. No faith in our company what-so-ever. I hope all of them get it wrong and this will cause a big noise in January.

0 · Reply

JohntyCT Dec. 22 at 3:03 PM

$PDSB we have some volume today… 🫣 … 200k traded by 10 am….

1 · Reply

Baltic_Roots Dec. 21 at 7:28 PM

$PDSB yes yes this is how long time I'm here, and if FDA will give agreen light Ivwill be here for next 2 years

0 · Reply

FesertBoy Dec. 20 at 2:30 PM

$PDSB I doubt that bum had and $PDSB left

0 · Reply

ThatNurseDude Dec. 20 at 2:38 AM

$PDSB Pharmdca officially closed his position in this company 🙃

3 · Reply

dvice2 Dec. 19 at 11:31 PM

$PDSB hard to know what will happen if we get positive FDA outcome.. it will basically validate the data and company’s strategy imo which should be worth a fuck ton.. im optimistic that it brings a lot of new eyes on this co. and maybe a real partnership finally. Negative outcome isnt something i want to think about.. cheers to everyone as we move into the new year - we all deserve some positive news here

2 · Reply

rwol9999 Dec. 19 at 3:10 PM

$PDSB wish I could buy more....... this wont stay under a buck much longer.

0 · Reply

Ontherag Dec. 19 at 3:05 PM

$PDSB L2 looks weird, very controlled on both sides of the bid

0 · Reply

rwol9999 Dec. 19 at 2:56 PM

$PDSB My guess is there getting ready to release the report and it was positive.

0 · Reply

rwol9999 Dec. 19 at 2:51 PM

$PDSB wow, I just saw an ad on c.N b c for p.D.S biotechnology seems like they're getting ready to make some moves.

3 · Reply

ThatNurseDude Dec. 18 at 11:33 PM

$PDSB seems like we won’t hear anything until official fda meeting minutes released at this point.

1 · Reply

Goodstockday Dec. 18 at 5:08 PM

$PYXS These are problematic results for many reasons. Low subject numbers. High side effects. This ADC is not targeting well. This is functioning like full on chemo. HPV-16 is treated by experts now as a separate group. They lump all HPV types together. This greatly impairs interpretation. HPV-16 is much less responsive to treatment. $PDSB has significantly better results with Versamune.

0 · Reply

Ydelaporte Dec. 17 at 8:54 PM

$PDSB ai…

0 · Reply

Ontherag Dec. 16 at 9:58 PM

$PDSB For anyone new or joining, just sit back and pray for business development 🙏

1 · Reply

Market Cap	43.75M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.26

Volume	151,600
Avg Vol	849,478
Day's Range	N/A - N/A
Shares Out	48.98M
Stochastic %K	21%
Beta	1.11
Analysts	Strong Sell
Price Target	$7.50